Q1 Earnings Estimate for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Avadel Pharmaceuticals in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at $0.00 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $1.65 EPS.

Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Avadel Pharmaceuticals in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price objective for the company. Piper Sandler reduced their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Wednesday, April 9th. Finally, UBS Group cut their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Avadel Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Stock Up 2.3 %

NASDAQ:AVDL opened at $7.91 on Wednesday. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $19.09. The company has a market cap of $764.34 million, a P/E ratio of -10.01 and a beta of 1.52. The business has a 50 day moving average price of $8.01 and a two-hundred day moving average price of $10.04.

Insider Buying and Selling

In related news, Director Linda Palczuk purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were acquired at an average price of $7.93 per share, for a total transaction of $39,650.00. Following the purchase, the director now owns 67,900 shares in the company, valued at approximately $538,447. This represents a 7.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. FMR LLC bought a new position in shares of Avadel Pharmaceuticals during the third quarter worth approximately $31,000. Hsbc Holdings PLC bought a new position in Avadel Pharmaceuticals during the 4th quarter worth $113,000. Kazazian Asset Management LLC acquired a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth $126,000. Sanctuary Advisors LLC bought a new stake in shares of Avadel Pharmaceuticals in the fourth quarter valued at about $140,000. Finally, Nations Financial Group Inc. IA ADV bought a new stake in shares of Avadel Pharmaceuticals in the fourth quarter valued at about $163,000. Institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.